$1.97
1.03% yesterday
Nasdaq, Sep 26, 10:00 pm CET
ISIN
US54303L1044
Symbol
LGVN
Sector
Industry

Longeveron Inc - Ordinary Shares - Class A Stock price

$1.97
-0.44 18.26% 1M
-1.47 42.68% 6M
-11.63 85.51% YTD
-20.33 91.17% 1Y
-35.63 94.76% 3Y
-98.03 98.03% 5Y
-98.03 98.03% 10Y
Nasdaq, Closing price Thu, Sep 26 2024
+0.02 1.03%
ISIN
US54303L1044
Symbol
LGVN
Sector
Industry

Key metrics

Market capitalization $12.38m
Enterprise Value $1.75m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 1.42
P/S ratio (TTM) P/S ratio 10.07
P/B ratio (TTM) P/B ratio 1.26
Revenue growth (TTM) Revenue growth 39.34%
Revenue (TTM) Revenue $1.23m
EBIT (operating result TTM) EBIT $-18.19m
Free Cash Flow (TTM) Free Cash Flow $-16.58m
Cash position $12.38m
EPS (TTM) EPS $-8.78
P/E forward negative
P/S forward 6.83
EV/Sales forward 0.97
Short interest 5.88%
Show more

Is Longeveron Inc - Ordinary Shares - Class A a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,900 stocks worldwide.

Longeveron Inc - Ordinary Shares - Class A Stock Analysis

Unlock Scores for Free

Analyst Opinions

2 Analysts have issued a Longeveron Inc - Ordinary Shares - Class A forecast:

2x Buy
100%

Analyst Opinions

2 Analysts have issued a Longeveron Inc - Ordinary Shares - Class A forecast:

Buy
100%

Financial data from Longeveron Inc - Ordinary Shares - Class A

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '24
+/-
%
1.23 1.23
40% 40%
100%
- Direct Costs 1.45 1.45
11% 11%
118%
-0.23 -0.23
69% 69%
-19%
- Selling and Administrative Expenses 10 10
14% 14%
815%
- Research and Development Expense 6.99 6.99
32% 32%
568%
-17 -17
13% 13%
-1,402%
- Depreciation and Amortization 0.95 0.95
0% 0%
77%
EBIT (Operating Income) EBIT -18 -18
13% 13%
-1,479%
Net Profit -19 -19
7% 7%
-1,513%

In millions USD.

Don't miss a Thing! We will send you all news about Longeveron Inc - Ordinary Shares - Class A directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Longeveron Inc - Ordinary Shares - Class A Stock News

Neutral
GlobeNewsWire
about 11 hours ago
Longeveron to attend Cell & Gene Meeting on the Mesa to highlight its cellular therapy program in Alzheimer's disease and CDMO facilities and services.
Neutral
GlobeNewsWire
about one month ago
MIAMI, Aug. 26, 2024 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, today announced that it will participate in the H.C. Wainwright 26th Annual Global Investment Conference taking place September 9-11, 2024 in New York City.
Neutral
Seeking Alpha
about one month ago
Longeveron, Inc. (NASDAQ:LGVN ) Q2 2024 Earnings Conference Call August 14, 2024 4:30 PM ET Company Participants Derek Cole - IR, Advisory Solutions Wa'el Hashad - CEO Nataliya Agafonova - CMO Lisa Locklear - CFO Joshua Hare - Co-Founder, Chief Science Officer & Chairman Conference Call Participants Ram Selvaraju - H.C. Wainwright Operator Good day, and welcome to Longeveron's 2024 Second Quart...
More Longeveron Inc - Ordinary Shares - Class A News

Company Profile

Longeveron LLC is a clinical stage biotechnology company that engages in the development of cellular therapies for specific aging-related and life-threatening conditions. Its lead product, LOMECEL-B, is a cell-based therapy product, which is derived from culture-expanded medicinal signaling cells that are sourced from bone marrow of young healthy adult donors. The company was founded by Joshua M. Hare and Donald M. Soffers in October 9, 2014 and is headquartered in Miami, FL.

Head office United States
CEO Mohamed Hashad
Employees 25
Founded 2014
Website www.longeveron.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today